HMD Stock Overview
Develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
HeraMED Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.021 |
52 Week High | AU$0.055 |
52 Week Low | AU$0.012 |
Beta | 0.084 |
11 Month Change | 0% |
3 Month Change | 50.00% |
1 Year Change | -61.82% |
33 Year Change | -92.08% |
5 Year Change | -90.23% |
Change since IPO | -88.33% |
Recent News & Updates
Recent updates
Shareholder Returns
HMD | AU Medical Equipment | AU Market | |
---|---|---|---|
7D | -4.5% | 2.0% | 0.7% |
1Y | -61.8% | 13.8% | 16.7% |
Return vs Industry: HMD underperformed the Australian Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: HMD underperformed the Australian Market which returned 16.7% over the past year.
Price Volatility
HMD volatility | |
---|---|
HMD Average Weekly Movement | 18.1% |
Medical Equipment Industry Average Movement | 9.8% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 17.2% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: HMD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: HMD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | n/a | Anoushka Gungadin | www.hera-med.com |
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus’ heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform.
HeraMED Limited Fundamentals Summary
HMD fundamental statistics | |
---|---|
Market cap | AU$13.30m |
Earnings (TTM) | -AU$6.73m |
Revenue (TTM) | AU$486.98k |
27.3x
P/S Ratio-2.0x
P/E RatioIs HMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HMD income statement (TTM) | |
---|---|
Revenue | AU$486.98k |
Cost of Revenue | AU$268.47k |
Gross Profit | AU$218.51k |
Other Expenses | AU$6.94m |
Earnings | -AU$6.73m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.011 |
Gross Margin | 44.87% |
Net Profit Margin | -1,381.03% |
Debt/Equity Ratio | 16.4% |
How did HMD perform over the long term?
See historical performance and comparison